Study on ligustrazine in reversing multidrug resistance of HepG2/ADM cell in vitro.
- Author:
Ying MEI
1
;
Yu-jun SHI
;
Guo-qing ZUO
;
Jian-ping GONG
;
Chang-an LIU
;
Xu-hong LI
;
Meng-jun REN
Author Information
- Publication Type:Journal Article
- MeSH: Calcium Channel Blockers; pharmacology; Carcinoma, Hepatocellular; metabolism; pathology; Cell Line, Tumor; Cytotoxicity, Immunologic; drug effects; Doxorubicin; metabolism; pharmacology; Drug Resistance, Multiple; drug effects; Drug Resistance, Neoplasm; drug effects; Genes, MDR; Glycoproteins; metabolism; Humans; Liver Neoplasms; metabolism; pathology; Pyrazines; pharmacology
- From: China Journal of Chinese Materia Medica 2004;29(10):970-973
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the reverse effect of ligustrazine (TMP) on HepG2/ADM, a herd of hepatocellular carcinoma cell, multidrug resistance (MDR) and the influence of P-gp170 expression.
METHODThe reverse effect of ligustrazine on HepG2/ADM cell was observed, with the methods of cell culture, MTT's analyze, RT-PCR and Flow cytometric, etc.
RESULTLigustrazine could make MDR of cell line of HepG2/ADM reduce the expression of P-gp170, enhance the density of adriamycin in cell and increase the adriamycin's cytotoxicity. With the Flow cytometric, the results of RT-PCR showed the transcriptional activity of the MDR1 decreased.
CONCLUSIONLigustrazine can reverse MDR of HCC cell line of HepG2/ADM and has prospect in clinical use.
